EUCTR2018-000031-28-DE进行中（未招募）1 期
A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients age 18 to 90 years of age inclusive
- •Diagnosis of type I or type II diabetes mellitus.
- •The Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye must be between 24 and 72 letters inclusive (approximate Snellen equivalent of 20/40-20/320). The non-study eye (fellow eye) should be =34 letters or better (approximate Snellen equivalent of 20/200) at screening
- •Presence of DME in the study eye, with decrease in vision due to foveal thickening of central macular thickness = 320µm in the central subfield, as assessed on spectral-domain ocular coherence tomography (SD-OCT) and confirmed by the central reading center at screeening
- •Sufficiently clear ocular media and adequate pupil dilation in the study eye to permit fundus photographs of adequate clarity to measure diameters of retinal arteries and veins at screening
- •Please refer to the protocol for a comprehensive list of inclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 55
排除标准
- •Patient with history of treatment for DME in the study eye as defined
- •by the following:
- •- IVT anti-vascular endothelial growth factor (VEGF) treatment within 90
- •days before baseline in the study eye. History or concurrent treatment
- •with these medications/procedures in the non study eye is permitted.
- •- Patient with history of intraocular corticosteroids in the study eye
- •including dexamethasone intravitreal implants during the 6 month
- •period prior to baseline. Any prior use of fluocinolone acetonide intravitreal implant (Iluvien) is prohibited regardless of timing.
- •Concomitant conditions or ocular disorders in the study eye which may, in the opinion of the investigator, confound the interpretation of study results, compromise visual acuity or require medical or surgical intervention during the study period:
- •- High risk proliferative diabetic retinopathy in the study eye, as per investigator assessment at both screening and baseline.
- •- Patients with the following conditions in the study eye at screening or baseline must be excluded: structural damage of the fovea, vitreous hemorrhage, retinal detachment, vitreomacular traction, macular hole, retinal vein/arterial occlusion, neovascularization of iris or choroidal neovascularization of any cause)
- •3. Laser photocoagulation (macular or panretinal) in the study eye during the 3-month period prior to baseline.
- •Patients, with type 1 or type 2 diabetes who have a hemoglobin A1C
- •= 12% at screening.
- •Any progressive disease of the retina in the study eye (e.g. uveitis,
- •rod-cone dystrophy) or optic nerve other than those listed in the
- •inclusion criteria.
- •Area of retinal ischemia involving the macula (as measured by the
- •foveal avascular zone) = 1000 µm in linear diameter.
- •Active intraocular inflammation (graded as trace or above) in either
- •eye or active intraocular infection in the study eye.
- •Active infection involving the study eye's ocular adnexa including
- •infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as
- •idiopathic or
- •autoimmune-associated uveitis in either eye, or intraocular infection in
- •either eye.
- •Any intraocular surgery (except uncomplicated cataract surgery) in the study eye within the past 6 months preceding Day 1. Uncomplicated cataract surgery (e.g. routine surgery with no intra or post operative complications) within the past 3 months preceding Day 1. Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within the past 30 days preceding baseline.
- •Current diagnosis of clinically significant anemia, or hemoglobin <10
- •g/dL for women and <11 g/dL for men.
- •Please refer to the protocol for a comprehensive list of exclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A Proof of concept study of intravitreal LKA651 in patients with macular edemaEUCTR2018-000031-28-ESovartis Farmacéutica, S.A.91
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)Ankylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-PTovartis Pharma AG859
进行中（未招募）
1 期
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASSEUCTR2017-000679-10-DEovartis Pharma AG837
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)Ankylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-ESovartis Farmacéutica, S.A.837
进行中（未招募）
1 期
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASSAnkylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-GRovartis Pharma AG837